Facing uncontrolled symptoms or disease progression with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)? The path to managing this condition might involve a closer look at how we use somatostatin analogs. Jennifer Chan, MD, MPH, a leading expert in the field, sheds light on the potential of dose escalation and interval adjustments with these medications, and how the SORENTO trial could redefine treatment approaches.
Dr. Chan suggests that increasing the dose or shortening the treatment interval of somatostatin analogs could be a viable strategy for patients with GEP-NETs who need better control of their symptoms or disease. But here's where it gets controversial...
In an interview during the 2025 NANETS Multidisciplinary NET Medical Symposium, Dr. Chan discussed the ongoing phase 3 SORENTO trial (NCT05050942). This trial is investigating a novel, highly bioavailable formulation of octreotide, which is self-administered. The goal is to determine if dose and bioavailability truly matter in treatment outcomes. The trial compares this new octreotide formulation (CAM2029) against standard doses of octreotide and lanreotide. The results could provide crucial insights into whether a more bioavailable formulation can offer superior efficacy.
Dr. Chan, who is the clinical director of the Gastrointestinal Cancer Center, director of the Program in Carcinoid and Neuroendocrine Tumors, and an institute physician at Dana-Farber Cancer Institute, and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts, highlighted key takeaways:
- Increasing octreotide LAR to 40 mg or 60 mg or shortening lanreotide intervals can improve the control of carcinoid syndrome symptoms like flushing and diarrhea.
- Observational data from trials such as NETTER-1, NETTER-2, and CLARINET FORTE suggest that higher doses or shorter dosing intervals may prolong disease stability.
- The ongoing phase 3 SORENTO trial is testing a novel, self-administered, highly bioavailable octreotide that could reshape somatostatin analog dosing paradigms.
So, what's the evidence supporting individualized dose adjustments?
Dr. Chan explains that physicians often adjust somatostatin analog doses, especially octreotide long-acting repeatable (LAR). If symptoms of carcinoid syndrome aren't well-controlled, they might increase the dose from the standard 30 mg to 40 mg or 60 mg. This can help manage symptoms like flushing and diarrhea. Data from trials like NETTER-1 and NETTER-2 suggest that even in patients with more advanced disease, or those who have progressed on standard doses, increasing the dose of octreotide LAR from 30 mg to 60 mg might provide a period of disease control.
The phase 2 CLARINET FORTE trial also showed that shortening the interval for lanreotide, another somatostatin analog, from the usual 120 mg every 4 weeks to 120 mg every 2 weeks, could offer progression-free survival benefits for patients who had progressed on standard therapy.
How do doctors decide when to adjust treatment?
In clinical practice, dose escalation is a common approach. For octreotide, doctors might increase the dose to 40 mg or 60 mg to help control symptoms. Uncontrolled carcinoid syndrome is a frequent reason for these adjustments. The same applies to lanreotide, where the 120 mg every 4 weeks dose might be given more frequently, such as every 3 or 2 weeks, primarily for symptom control. This aligns with guidelines from the National Comprehensive Cancer Network, which support dose adjustments for symptom management.
And this is the part most people miss... While there's more evidence for dose adjustments for symptom control, data on dose escalation for disease control is still emerging. Observational results from other studies suggest that disease control may be achievable, but we await further trial results to better understand this.
What do you think? Are you surprised by the potential benefits of dose escalation? Do you have any questions about these treatment strategies? Share your thoughts in the comments below!
